Anbio BiotechnologyNNNN -4.13%24 PS Ratio is 57.74 as of Jul. 08, 2026, which is 55% below its 10-year median of 129.55. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Anbio Biotechnology ranks worse than 95.4% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Anbio Biotechnology's share price is $11.49.
Anbio Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.20. Hence, Anbio Biotechnology's PS Ratio for today is 57.74.
Good Sign:
Anbio Biotechnology stock PS Ratio (=60.53) is close to 1-year low of 60.53.
The historical rank and industry rank for Anbio Biotechnology's PS Ratio or its related term are showing as below:
NNNN'
s PS Ratio Range Over the Past 10 Years
Min: 31.02 Med: 129.55 Max: 274.52
Current: 57.74
During the past 5 years, Anbio Biotechnology's highest PS Ratio was 274.52. The lowest was 31.02. And the median was 129.55.
NNNN's PS Ratio is ranked worse than 95.4% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.935
vs NNNN: 57.74
During the past 5 years, Anbio Biotechnology's highest 3-Year average Revenue per Share Growth Rate was 61.70% per year. The lowest was 6.50% per year. And the median was 34.10% per year.
Back to Basics: PS Ratio
Anbio Biotechnology (NAS:NNNN) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Anbio Biotechnology PS Ratio Related Terms
Anbio Biotechnology PS Ratio Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's PS Ratio distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Anbio Biotechnology's Share Price of today is $11.49.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Anbio Biotechnology's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.20.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Anbio Biotechnology (NNNN) has a PS Ratio of 57.74 as of Jul. 08, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Anbio Biotechnology and its competitors. This is 55% below median its historical median of 129.55. Over the past decade, Anbio Biotechnology's PS Ratio has ranged from 31.02 to 274.52. According to the industry distribution chart, Anbio Biotechnology ranks #767 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 95.4%.
Is Anbio Biotechnology's PS Ratio too high?
Anbio Biotechnology's current PS Ratio of 57.74 is 55% below median its 10-year median of 129.55. Over the past 10 years, this metric has ranged from a low of 31.02 to a high of 274.52. The Medical Devices & Instruments industry median PS Ratio is 2.94. Anbio Biotechnology's value of 57.74 is 1867.3% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #767 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's PS Ratio compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #767 out of 804 companies for PS Ratio. This places Anbio Biotechnology in the lower half of its industry. The industry median PS Ratio is 2.94. Anbio Biotechnology's value of 57.74 is 1867.3% above this benchmark. Historically, Anbio Biotechnology's own PS Ratio has ranged from 31.02 to 274.52 over the past decade. While the company's 10-year median is 129.55 vs. the industry median of 2.94, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current PS Ratio of 57.74 is 1867.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current PS Ratio is 57.74, which is 55% below median its own 10-year median of 129.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current PS Ratio of 57.74. The current PS Ratio is 57.74, which is 55% below median its 10-year median of 129.55 and 1867.3% above the Medical Devices & Instruments industry median of 2.94. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current PS Ratio is 57.74 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
